Evoke Pharma - 13 Year Stock Price History | EVOK
Historical daily share price chart and data for Evoke Pharma since 2013 adjusted for splits and dividends. The latest closing stock price for Evoke Pharma as of February 27, 2026 is 29.90.
- The all-time high Evoke Pharma stock closing price was 2014.56 on October 04, 2013.
- The Evoke Pharma 52-week high stock price is 32.50, which is 8.7% above the current share price.
- The Evoke Pharma 52-week low stock price is 2.46, which is 91.8% below the current share price.
- The average Evoke Pharma stock price for the last 52 weeks is 12.00.
| Evoke Pharma Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 26.1817 | 22.1500 | 31.0000 | 21.9000 | 29.9000 | 34.68% |
| 2025 | 5.7474 | 4.4700 | 24.2000 | 2.0700 | 22.2000 | 402.26% |
| 2024 | 6.1665 | 12.3600 | 12.8400 | 3.8700 | 4.4200 | -64.93% |
| 2023 | 23.0008 | 32.4012 | 69.0000 | 11.5488 | 12.6036 | -60.81% |
| 2022 | 45.3896 | 85.3056 | 123.8400 | 17.2476 | 32.1600 | -59.39% |
| 2021 | 228.7462 | 388.8000 | 635.0400 | 79.2000 | 79.2000 | -78.68% |
| 2020 | 408.0478 | 230.4000 | 820.8000 | 118.0660 | 371.5200 | 59.26% |
| 2019 | 184.8911 | 367.2000 | 460.8000 | 76.3488 | 233.2800 | -34.68% |
| 2018 | 368.5193 | 338.4000 | 479.5200 | 273.6000 | 357.1200 | 9.73% |
| 2017 | 398.2520 | 298.0800 | 558.7200 | 298.0800 | 325.4400 | 11.88% |
| 2016 | 504.3054 | 469.4400 | 1568.1600 | 207.3600 | 290.8800 | -38.79% |
| 2015 | 719.6800 | 869.7600 | 1130.4000 | 368.6400 | 475.2000 | -44.07% |
| 2014 | 1087.1333 | 1110.2400 | 1707.8400 | 679.6800 | 849.6000 | -20.81% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |